|  |
| Merck Signs $100M Development Deal with Ranbaxy
| In a win-win situation for both companies, Merck gets access to one of the hottest generics firms in the world while Ranbaxy gets a chance to hang with the big boys. | | | GSK Snags Sirtris for $720M
| | Small biotech company is creating a buzz with a diabetes drug that incorporates a component found in red wine. Pharm Exec talks to Sirtris CEO Christoph Westphal about the merger and the battle against diseases of aging. | | | Takeda Picks Up Millennium
| | Japanese drugmaker buys the cancer-specialist biotech for a whopping $8.8 billion. | | | 2007 in M&A: 44 deals, $79 billion
| | The year in pharma and biotech finance. Stock prices stabilized. Pharma M&A kept building. And the mid-cap biotechs finally got a little love. | |
| | Big Deals
| | Many say licensing is the new R&D. We've rounded up the unions to watch from the third quarter of 2007. | | | GSK to Pay $1 Billion for Synta Melanoma Drug
| | In a blockbuster codevelopment deal, GlaxoSmithKline gains rights to an innovative Phase III melanoma drug. | | | M&A: Panning for Gold
| | here's a solid case to be made for choosing A. The market for deals has been robust through the first half of 2007. A Cowen research report counted 10 public deals done by July 2007, compared with 14 for all of 2006. Another data source, Irving Levin Associates, cites 455 public and private healthcare deals in the first six months of 2007, a 12 percent decrease from the same period last year—but an 18 percent rise in deal value. | | | Novartis to Intercell: "Gimme All Your Vax."
| | But is the pharma-biotech vaccine deal a prelude to a takeover? | | | Roche to Ventana: "Let's Make A Deal"
| | ...And the spurned suitor won't take "No" for an answer
| |  MORE ARTICLES
|
| |
| |
| Tightening the Chain
| | EU makes plans to police its supply chain | | | British Biotech Blues
| | Can ceasing trade sales and finding funding help UK biotechs became an industry in their own right? | | | Fire and NICE
| | UK agency takes the heat for slow evaluations and failing to consider societal benefits of new drugs | | | Wholesale Change: UK Responds to the Single-Supplier Practice
| | Will the sole-wholesaler approach mean higher costs for NHS?
| | | Oxfam Points Finger
| | Pharma defends itself against claims made in charity's report on drug access for the world's poor | | | Inviting Innovation
| | One of industry's main complaints is that delaying the introduction of new medicines is a particularly simple way of saving money | | | India vs. China
| | Will CROs continue to operate in India, or will Novartis' pullout send them farther East? | | | Some Alzheimer's Patients Left Behind
| | A landmark court case in the United Kingdom has left Alzheimer's patients with mild to moderate disease unable to receive any of the three drugs that might help them—Aricept (donepezil), Reminyl (galantamine), and Exelon (rivastigmine). Eisai and Pfizer, which make and market Aricept, had challenged the ruling made last year by the National Institute for Clinical Excellence that the drugs should be prescribed only to patients in the later stages of the disease. They were granted a judicial review—the first time one of NICE's decisions had been challenged in this way—and while the judge upheld one part of the challenge, the other two parts were dismissed and NICE's guidance stands. | | | Incentives Incense Industry in UK
| | The Association of the British Pharmaceutical Industry is challenging the UK government over the financial incentives being offered by the Department of Health (DH) to encourage doctors to switch patients from on-patent medicines to specific generic alternatives. ABPI believes the way the incentives are structured contravenes EU law—if pharma companies were to offer similar payments, they would be in serious trouble. | | | MORE ARTICLES
|
| |
| India: An Emerging Knowledge Superpower
| | "India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we are on our way to become a R&D hub." For Dilip Shah, General Secretary of the Indian Pharmaceutical Alliance (IPA), India is currently on its way to undertake one of the greatest transformations ever experienced within the pharmaceutical industry, although the excitement has been over 30 years in the making. | | | MORE ARTICLES
|
| |
| New Educational Program to Boost PR Compliance
| | With the launch of the Center for Communication Compliance, pharma companies and PR firms have a one-stop resource to educate themselves about marketing regulations in an effort to reduce accidental non-compliance. | | | AMA Tables Plan to Ban CME Funding
| | The American Medical Association's proposal to keep pharma from funding CME programs was put on hold for further review. But don?t expect the plan to disappear for good. | | | Pharma to Sit on DTC Ads
| | On Monday, a handful of Big Pharma companies told Congress that they would put a six-month moratorium on drug ads for recently approved medication. Pfizer, Merck, Schering-Plough, and Johnson & Johnson also agreed to closely follow the American Medical Association's guidelines when using actors playing physicians in advertisements. | | | Mightier Than the Sword
| | When it comes to marketing, every syllable speaks volumes | | | The Web Video (R)evolution
| | Pharma is taking note of online video's power to affect B2B communications | | | Doctor's Orders
| | Dr. Michael Kessler and Mark Vitello of MD Mindset have the cure for the common sales pitch? Look at the transaction from the customer's perspective | | | Dial FDA: Marketers Face Added DTC Requirements
| | Feds consider adding an 800 number to television ads for adverse event reporting. Does this shine light on DTC ads while pushing public health goals? Industry is mum on the topic | | | Red Cross Gets OK to Market Emblem
| | American Red Cross scores a win against Johnson & Johnson in a legal battle over the use of one of the healthcare?s most recognizable symbols | | | Shire Reminder Promo a No No
| | FDA takes the opportunity to remind industry what reminder ads are, as promotional material for Shire's Fosrenol is deemed in violation of advertising rules | | | MORE ARTICLES
|
| |
| |
| BioMS Medical Signs $500 Million Agreement with Lilly
| | Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS. | | | Data Mining Companies Score Legal Win in Maine
| | IMS Health, and a handful of other intelligence gathering companies, will be allowed to collect prescribing information from physicians in Maine. This is a big win for pharma companies that purchase reports from data mining companies to better market to doctors. The last hurdle is Vermont, which still has an outstanding lawsuit against the firms. | | | New Study Reveals Distribution Trends in Drug Sampling
| | Drug sampling is way up, but who is receiving the free medication? The American Journal of Public Health states that the majority of samples are distributed to the wealthy and insured. PhRMA, however, disagrees. | | | Preemption Gets Boost from Bush
| | State and federal governments do battle over who is responsible for faulty or mislabeled drugs and devices, while patients, pharma manufacturers, and Medtronic wait for answers. Is federal preemption the answer? | | | BMS Cuts Bloated Manufacturing Arm to Bolster R&D
| | Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing. | | | Chantix Concerns Prompt FDA Investigation
| | Side effects associated with Pfizer?s smoking-cessation drug have caused a stir in the blogosphere, prompting FDA to seek further information about incidents of depression and suicidal thoughts. | | | Duke Partners with FDA to Modernize Clinical Trials
| | In an attempt to bring clinical trials into the 21st century, FDA and Duke launched a public–private partnership that will look at the current state of trials and determine what tools can be implemented to make trials safer and more efficient. | | | FDA Recommends Precautionary Warnings for This Season's Flu Drugs
| | An FDA review team advised that flu vaccines manufactured by GSK and Roche include precautionary warnings citing the potential for neuropsychiatric side effects. Adverse events have been reported in Japan, and now the United States is starting to pay attention. | | | J&J vs. Red Cross: The Battle Continues
| | Court rejects one of J&J's eight claims, but trademark dispute case will proceed. | | | MORE ARTICLES
|
| |
| |
|
|
| 
